- Individuals 18 years of age and older
- 2x 0.5 ml doses given IM (deltoid)
- The 2nd dose should be given 28 days after the 1st
- The manufacturer recommends a 28-day interval; however, NACI recommends a minimum interval of 21 days between doses (any doses provided at an earlier interval would be considered invalid and need to be repeated).
- Summary: Ideally, the 2nd dose is given at 28 days after the 1st dose.
- It must be given at least 21 days after the 1st dose, otherwise the 2nd dose will need to be repeated.
- If the 2nd dose is given later than 28 days, there is no need to restart the series, but full protection requires both doses.
- NOTE: As of March 3, 2021, NACI recommends that in the context of limited COVID-19 vaccine supply, jurisdictions should maximize the number of individuals benefiting from the first dose of vaccine by extending the interval for the second dose of vaccine to 4 months. This recommendation is subject to revision as evidence evolves.
Only short-term data are available at this time. Surveillance will continue for long-term adverse effects.
Reported adverse effects were mild or moderate, resolved within a few days and included:
- pain at the injection site
Adverse effects were more common following the 2nd dose.
There are no known drug interactions. However, if a patient is immunosuppressed by medication or disease state, they should not receive the vaccine at this time. Immunosuppressive medications include high dose steroids and certain biologics; more examples can be found here.
- Under 18 years of age
- COVID-19 Vaccine Moderna is approved for use in persons 18 years of age and older.
- There are no safety and efficacy data for children and adolescents younger than 18 years.
- Certain populations (see below) have been excluded from the initial vaccine trials. At this time, NACI recommends that a risk-benefit analysis be conducted for these populations, including that the vaccine recipient/caregiver understands the absence of evidence of the safety and effectiveness in these populations at this time. If benefit outweighs risk (e.g. someone in one of these groups who cannot avoid potential exposure to the virus) and the client is in the authorized age group, the vaccine should be offered. At this time, there are no known harms in these populations. See the NACI Statement for more information regarding these populations and risk assessment. These populations include those who are/have:
- Immunosuppressed from disease or treatment
- See the Canadian Immunization Guideline Part 3 – Vaccination of Specific Populations for definitions and general additional information.
- Autoimmune conditions
- See the Canadian Immunization Guideline Part 3 – Vaccination of Specific Populations for additional general information on autoimmune disorders and chronic inflammatory diseases.
- Currently pregnant or planning pregnancy before receiving both doses
- NACI recommends delaying pregnancy until at least 28 days after the last dose to be prudent. However, receipt of vaccine before this time period is not a reason to terminate pregnancy.
- The Society of Obstetricians and Gynaecologists of Canada (SOGC)- Statement on COVID-19 Vaccination in Pregnancy
- Currently breastfeeding
- Immunosuppressed from disease or treatment
- History of anaphylaxis following previous doses of the vaccine.
- Reported hypersensitivity to one of the ingredients. See product monograph for ingredients.
- polyethylene glycol (PEG) is a potentially allergenic ingredient
- See the Health Canada recommendations for people with serious allergies.
- Currently feeling unwell with symptoms that could be COVID-19 infection.
- to avoid confusion if symptoms worsen as they could be adverse effects of the vaccine or because of the underlying infection
- to prevent potential transmission to others who are at the vaccine clinic/site (clients should be encouraged to follow public health quarantine recommendations)
- Serious adverse or allergic reaction to previous dose of COVID-19 vaccine unless determined safe by an allergist or other healthcare provider.
- Clients with current infection should not present for vaccination to prevent transmission to others at the vaccination clinic/site and should follow public health quarantine recommendations.
- If acute symptoms have resolved and all quarantine orders have been followed, the client can be vaccinated.
- However, the recommendation is for clients to wait 3 months to take advantage of the client's natural immunity and to leave the current supply of vaccine for others without immunity.
No. At this time, NACI is recommending:
- The COVID-19 vaccines should be administered at least 14 days AFTER any other vaccines (live or inactivated).
- Other vaccines should be avoided for 28 days AFTER receiving the last COVID-19 vaccine dose.
- Exception: If a patient requires a vaccination as part of a post-exposure prophylaxis protocol, it should be administered.